Seeking Alpha

Galena Biopharma (GALE) +15.5% premarket after data from a clinical trial of NeuVax presented at...

Galena Biopharma (GALE) +15.5% premarket after data from a clinical trial of NeuVax presented at ASCO reveals booster inoculations are well-tolerated and appear to maintain long-term peptide-specific immunity and reduce disease recurrence rates. Cantor Fitzgerald starts coverage of GALE at Buy, saying its breast cancer treatment "would represent major advances in prevention of disease."
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs